Healios KK (4593) Price & Analysis

Compare

6 Followers

4593 Stock Chart & Stats

¥304.00

¥3.00(1.60%)

At close: Jan 08 4:00 PM EST

¥304.00

¥3.00(1.60%)

Day’s Range― - ―

52-Week Range¥194.00 - ¥747.00

Previous CloseN/A

Volume811.70K

Average Volume (3M)1.65M

Market Cap

¥42.47B

Enterprise Value¥38.60B

Total Cash (Recent Filing)¥6.50B

Total Debt (Recent Filing)¥2.63B

Price to Earnings (P/E)―

Beta1.04

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)18.90

Shares Outstanding115,727,200

10 Day Avg. Volume1,843,110

30 Day Avg. Volume1,654,023

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)7.59

Price to Sales (P/S)27.96

P/FCF Ratio-8.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥800.00

Price Target Upside163.16% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regenerative Medicine FocusA focused business model on regenerative medicine and cell therapy targets high-unmet-need areas with strong scientific barriers to entry. That specialization supports durable competitive differentiation, long product development cycles, and potential premium pricing and partnership interest over the medium term.

Partnership-driven Revenue ModelReliance on partnerships, milestone payments and royalties provides diversified, non-dilutive funding and external commercialization support. Structural collaborations can extend runway, validate technology, and accelerate market access, improving scaling prospects over the next several quarters.

Improving Free Cash Flow GrowthA 28.6% improvement in free cash flow growth signals operational progress toward cash generation even with negative absolute cash flows. If sustained, this trend reduces financing pressure, improves sustainability of R&D spending, and materially affects liquidity over a 2-6 month horizon.

Bears Say

Declining Revenue TrendA meaningful TTM revenue decline undermines commercialization momentum and weakens the company’s ability to fund ongoing R&D from internal sources. Persistent revenue contraction strains scalability and makes long-term planning and investment less sustainable without external capital or new partnership wins.

Large, Persistent Losses And Negative MarginsDeep negative margins across gross profit, EBIT and EBITDA indicate the business is far from break-even. Sustained losses erode equity, increase reliance on external financing, and can force strategic compromises or dilution, limiting the firm’s ability to execute long-term development plans.

High Leverage And Weak Cash ConversionA debt-to-equity ratio above 2.0 combined with negative operating cash flow raises refinancing and liquidity risk. High leverage limits strategic flexibility and increases vulnerability to funding shocks, making sustained investment in clinical programs and commercialization harder without additional capital.

Healios KK News

Healios Issues FY2025 Results With Strong Caution on Forward-Looking Data

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. released its FY2025 financial results materials primarily...

19h ago

4593

Healios Launches Japan Arm of Global Phase 3 Trial for ARDS Stem Cell Therapy

An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has begun preparations to initiate...

14d ago

4593

Healios Deepens Alfresa Alliance for Stem Cell Culture Supernatant Distribution in Japan

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. has signed a letter of intent with...

27d ago

4593

Healios Files Japan Trial Plan for Global Phase 3 ARDS Stem Cell Study

Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has submitted a clinical trial plan notification...

28d ago

4593

Healios Faces ¥120 Million Lawsuit Over Joint Research Deal but Says Business Policy Unchanged

Healios KK ( ($JP:4593) ) has issued an update. Healios K.K. disclosed that a lawsuit has been filed...

2M ago

4593

Healios K.K. Announces Key Management Changes and New Division

Healios KK ( ($JP:4593) ) has issued an announcement. Healios K.K. has announced changes in its management and...

2M ago

4593

Healios KK Advances ARDS Treatment Development with Global Study Plans

Healios KK ( ($JP:4593) ) has issued an update. Healios KK announced its development policy for HLCM051, prioritizing...

2M ago

4593

Healios K.K. Releases FY2025 Q3 Financial Results

Healios KK ( ($JP:4593) ) has shared an announcement. Healios K.K. has released its financial results for the...

3M ago

4593

Healios Partners with Kyushu University for Brain Tumor Therapy Research

The latest update is out from Healios KK ( ($JP:4593) ). Healios K.K. has entered into a joint...

4M ago

4593

Healios Ends Alliance with Nikon, Plans CDMO Expansion

Healios KK ( ($JP:4593) ) has shared an update. Healios K.K. has announced the termination of its business...

4M ago

4593

4593 FAQ

What was Healios KK’s price range in the past 12 months?

Healios KK lowest stock price was ¥194.00 and its highest was ¥747.00 in the past 12 months.

What is Healios KK’s market cap?

Healios KK’s market cap is ¥42.47B.

When is Healios KK’s upcoming earnings report date?

Healios KK’s upcoming earnings report date is May 20, 2026 which is in 92 days.

How were Healios KK’s earnings last quarter?

Healios KK released its earnings results on Feb 16, 2026. The company reported ¥18.9 earnings per share for the quarter, beating the consensus estimate of ¥4.65 by ¥14.25.

Is Healios KK overvalued?

According to Wall Street analysts Healios KK’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Healios KK pay dividends?

Healios KK does not currently pay dividends.

What is Healios KK’s EPS estimate?

Healios KK’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Healios KK have?

Healios KK has 115,727,200 shares outstanding.

What happened to Healios KK’s price movement after its last earnings report?

Healios KK reported an EPS of ¥18.9 in its last earnings report, beating expectations of ¥4.65. Following the earnings report the stock price went down -0.216%.

Which hedge fund is a major shareholder of Healios KK?

Currently, no hedge funds are holding shares in JP:4593

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Healios KK

Healios KK (4593) is a biotechnology company based in Japan that focuses on the research, development, and commercialization of innovative therapies and solutions for various medical conditions. The company primarily operates in the healthcare sector, with a strong emphasis on regenerative medicine and cell therapy. Healios aims to address unmet medical needs through its core products, which include advanced treatments for neurological disorders, cancer, and other serious illnesses, leveraging cutting-edge technologies and scientific research.

Healios KK (4593) Earnings & Revenues

Historic Earnings Reports

4593 Stock 12 Month Forecast

Average Price Target

¥800.00

▲(163.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"217":"¥217","363":"¥363","509":"¥509","655":"¥655","801":"¥801"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥800.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥800.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[217,363,509,655,801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274,314.46153846153845,354.9230769230769,395.38461538461536,435.8461538461538,476.30769230769226,516.7692307692307,557.2307692307693,597.6923076923076,638.1538461538462,678.6153846153845,719.0769230769231,759.5384615384615,{"y":800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274,314.46153846153845,354.9230769230769,395.38461538461536,435.8461538461538,476.30769230769226,516.7692307692307,557.2307692307693,597.6923076923076,638.1538461538462,678.6153846153845,719.0769230769231,759.5384615384615,{"y":800,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,274,314.46153846153845,354.9230769230769,395.38461538461536,435.8461538461538,476.30769230769226,516.7692307692307,557.2307692307693,597.6923076923076,638.1538461538462,678.6153846153845,719.0769230769231,759.5384615384615,{"y":800,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":218,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":218,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":432,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":637,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":543,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":499,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":492,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":466,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":274,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >